Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Tecentriq | NSCLC

US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Early NSCLC

Posted on October 18, 2021
Post Views: 280

Tecentriq | NSCLCThe US Food and Drug Administration (FDA) has approved Roche’s Tecentriq or atezolizumab as adjuvant treatment for patients with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1=1%, as determined by FDA-approved test. This approval was based on results from an interim analysis of Phase III IMpower010 study. Roche has an extensive development program for Tecentriq including studies evaluating it alone and in combination with other medicines as well as studies in adjuvant settings across various types of tumors.

Tecentriq has previously shown clinically proven benefits in various types of lung cancer. It was also first approved cancer immunotherapy for front-line treatment of adults with small cell lung cancer in combination with carboplatin and chemotherapy. Tecentriq has also four approved indications in advanced NSCLC as single agent or in combination with targeted therapies and chemotherapies.

Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development said, “Tecentriq is now the first and only cancer immunotherapy available for adjuvant treatment of NSCLC, introducing a new era where people diagnosed with early lung cancer may have the opportunity to receive immunotherapy to increase their chances for cure.” “Today’s landmark approval gives physicians and patients a new way to treat early lung cancer that has the potential to significantly reduce risk of cancer recurrence, after more than a decade with limited treatment advances in this setting,” he added.

The results showed Tecentriq treatment, following surgery and platinum-based chemotherapy, reducing the risk of disease recurrence or death by 34% whose tumors expresses PD-L1≥1%, compared with best supportive care (BSC). Many patients with early-stage lung cancer experience disease recurrence following surgery. With availability of immunotherapy with surgery and chemotherapy, it offers patients new powerful tool to reduce the risk of relapse of lung cancer. This approval is important to screen lung cancer early and test for PD-L1 at diagnosis to help patients.

The information shared in this blog is for educational purposes only. Please contact your healthcare practitioner for any medical advice.

Subscribe to our newsletter or follow us on Twitter or Facebook today and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,324)
  • Lung Cancer: Symptoms and Treatment (5,657)
  • What is Non-Small-Cell Lung Cancer? (5,552)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d